Amlodipine-Simvastatin Drug Interaction
Yes, amlodipine does increase simvastatin blood concentrations, though the increase is considered minor and clinically manageable with appropriate dose limitations.
Mechanism and Magnitude of Interaction
Amlodipine causes a minor but measurable increase in simvastatin exposure through CYP3A4 inhibition. Both drugs are metabolized by the CYP3A4 enzyme system, and amlodipine acts as a weak inhibitor of this pathway 1.
The pharmacokinetic data demonstrates:
- 77% increase in simvastatin exposure when amlodipine 10 mg is co-administered with simvastatin 80 mg 1
- Approximately 46% increase in simvastatin bioavailability and 13% decrease in clearance with amlodipine 10 mg 2
- Increased peak concentration (Cmax) from 9.6 to 13.7 ng/ml and AUC from 34.3 to 43.9 ng·h/ml 3
Importantly, this interaction is dose-dependent - higher amlodipine doses produce greater increases in simvastatin levels.
Clinical Recommendations
The American Heart Association guidelines explicitly state that simvastatin doses >20 mg daily when coadministered with amlodipine are not recommended 4.
The FDA drug label for amlodipine reinforces this: "Limit the dose of simvastatin in patients on amlodipine to 20 mg daily" 1.
Practical Management Algorithm:
If patient is on amlodipine (any dose):
- Maximum simvastatin dose = 20 mg daily
- Do not exceed this limit regardless of amlodipine dose
If higher statin intensity is needed:
- Switch to a non-CYP3A4 metabolized statin (pravastatin, rosuvastatin, or pitavastatin)
- These statins show no significant interaction with amlodipine 4
Monitor for myopathy symptoms:
- Muscle pain, weakness, or tenderness
- Though real-world data suggests clinical myopathy rates are not significantly elevated with this combination 5
Important Caveats
The interaction is less severe than with diltiazem or verapamil, which cause moderate (3-5 fold) increases in simvastatin exposure and have even stricter dose limits (≤10 mg simvastatin) 4.
Asian patients require extra caution with statin-calcium channel blocker combinations due to potential ethnic differences in drug metabolism 4.
Non-concurrent dosing (separating administration times by 4 hours) may reduce the interaction by approximately 34-37%, but this strategy is not formally recommended in guidelines 6.
The cholesterol-lowering efficacy of simvastatin is maintained despite the interaction 3, and large-scale real-world data shows no increased frequency of muscular complaints compared to control groups 5.